Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 383.68
TGTX's Cash to Debt is ranked higher than
56% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. TGTX: 383.68 )
Ranked among companies with meaningful Cash to Debt only.
TGTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 383.68
Equity to Asset 0.89
TGTX's Equity to Asset is ranked higher than
83% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TGTX: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
TGTX' s Equity to Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.88 Max: 0.97
Current: 0.89
0.16
0.97
F-Score: 3
Z-Score: 14.89
M-Score: 6.79
WACC vs ROIC
12.30%
-311.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -41164.47
TGTX's Operating margin (%) is ranked lower than
97% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. TGTX: -41164.47 )
Ranked among companies with meaningful Operating margin (%) only.
TGTX' s Operating margin (%) Range Over the Past 10 Years
Min: -141552.63  Med: -39112.17 Max: -15109.21
Current: -41164.47
-141552.63
-15109.21
Net-margin (%) -40934.21
TGTX's Net-margin (%) is ranked lower than
97% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. TGTX: -40934.21 )
Ranked among companies with meaningful Net-margin (%) only.
TGTX' s Net-margin (%) Range Over the Past 10 Years
Min: -95121.05  Med: -39055.93 Max: -13472.37
Current: -40934.21
-95121.05
-13472.37
ROE (%) -59.09
TGTX's ROE (%) is ranked lower than
67% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. TGTX: -59.09 )
Ranked among companies with meaningful ROE (%) only.
TGTX' s ROE (%) Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -59.09
-3919.22
-40.04
ROA (%) -53.47
TGTX's ROA (%) is ranked lower than
72% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. TGTX: -53.47 )
Ranked among companies with meaningful ROA (%) only.
TGTX' s ROA (%) Range Over the Past 10 Years
Min: -543.33  Med: -90.73 Max: 6.57
Current: -53.47
-543.33
6.57
ROC (Joel Greenblatt) (%) -3493.95
TGTX's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. TGTX: -3493.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TGTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -58800  Med: -13407.82 Max: -6775.91
Current: -3493.95
-58800
-6775.91
Revenue Growth (3Y)(%) 44.20
TGTX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. TGTX: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TGTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 44.2
Current: 44.2
0
44.2
EBITDA Growth (3Y)(%) -10.60
TGTX's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. TGTX: -10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TGTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.00 Max: 52.1
Current: -10.6
0
52.1
» TGTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

TGTX Guru Trades in Q3 2014

Jim Simons 11,199 sh (New)
» More
Q4 2014

TGTX Guru Trades in Q4 2014

Jim Simons 157,881 sh (+1309.78%)
» More
Q1 2015

TGTX Guru Trades in Q1 2015

Jim Simons 19,399 sh (-87.71%)
» More
Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:VNLPY, NAS:ARWR, NAS:TRVN, NAS:VYGR, NAS:BLCM, NAS:CGEN, NAS:AGEN, NAS:SVA, NAS:PGNX, OTCPK:MEOBF, NAS:NDRM, NAS:ASND, NAS:VSAR, OTCPK:ELVAF, NAS:MYOK, NAS:LJPC, NAS:CTMX, NAS:VTAE, NAS:TLGT, NAS:CYTK » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Ratios

vs
industry
vs
history
P/B 3.66
TGTX's P/B is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. TGTX: 3.66 )
Ranked among companies with meaningful P/B only.
TGTX' s P/B Range Over the Past 10 Years
Min: 2.51  Med: 6.16 Max: 16.26
Current: 3.66
2.51
16.26
P/S 1512.50
TGTX's P/S is ranked lower than
98% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. TGTX: 1512.50 )
Ranked among companies with meaningful P/S only.
TGTX' s P/S Range Over the Past 10 Years
Min: 558.33  Med: 2217.50 Max: 4670
Current: 1512.5
558.33
4670
Current Ratio 7.94
TGTX's Current Ratio is ranked higher than
69% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. TGTX: 7.94 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.56 Max: 35.5
Current: 7.94
0.06
35.5
Quick Ratio 7.94
TGTX's Quick Ratio is ranked higher than
70% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. TGTX: 7.94 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.56 Max: 35.5
Current: 7.94
0.06
35.5
Days Sales Outstanding 393.82
TGTX's Days Sales Outstanding is ranked lower than
95% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. TGTX: 393.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 206.51 Max: 446.64
Current: 393.82
64.84
446.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.80
TGTX's Price/Net Cash is ranked lower than
57% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. TGTX: 6.80 )
Ranked among companies with meaningful Price/Net Cash only.
TGTX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.19  Med: 7.71 Max: 579.04
Current: 6.8
1.19
579.04
Price/Net Current Asset Value 5.45
TGTX's Price/Net Current Asset Value is ranked lower than
52% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. TGTX: 5.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TGTX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.18  Med: 7.25 Max: 3281.25
Current: 5.45
1.18
3281.25
Price/Tangible Book 3.69
TGTX's Price/Tangible Book is ranked higher than
54% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. TGTX: 3.69 )
Ranked among companies with meaningful Price/Tangible Book only.
TGTX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.65  Med: 6.96 Max: 5273.43
Current: 3.69
0.65
5273.43
Price/Median PS Value 0.68
TGTX's Price/Median PS Value is ranked higher than
68% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. TGTX: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
TGTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.72 Max: 1.86
Current: 0.68
0.01
1.86
Earnings Yield (Greenblatt) (%) -22.70
TGTX's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. TGTX: -22.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TGTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -22.69  Med: 194.40 Max: 1470.1
Current: -22.7
-22.69
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.31
Beta1.37
Short Percentage of Float23.44%
52-Week Range $6.00 - 19.05
Shares Outstanding (Mil)54.34

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 0 3 19
EPS ($) -1.25 -1.35 -1.29
EPS w/o NRI ($) -1.25 -1.35 -1.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:TGTX

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 

More From Other Websites
TG THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 14 2016
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps... Jun 10 2016
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps... Jun 10 2016
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference Jun 09 2016
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference Jun 09 2016
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL... Jun 07 2016
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL... Jun 07 2016
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events Jun 06 2016
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety... Jun 06 2016
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety... Jun 06 2016
TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 02 2016
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of... Jun 02 2016
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of... Jun 02 2016
Top Analyst Upgrades and Downgrades: Dollar General, Monsanto, Palo Alto, TG Therapeutics, Ulta,... May 27 2016
TG Therapeutics Strikes Global Alliance To Develop Novel BET Inhibitors For Hematological... May 27 2016
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors... May 27 2016
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors... May 27 2016
Coverage initiated on TG Therapeutics by SunTrust May 27 2016
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology... May 20 2016
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology... May 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)